Dr Cindy Ru | EVP & CSO
CRC Oncology Corp.

Dr Cindy Ru, EVP & CSO, CRC Oncology Corp.

Dr. Ru holds over 10 years of comprehensive experience in Global Oncology Clinical Development, Registration Submission and Product Launch. She has taken increasing responsibility and leadership roles in prestigious global pharmaceutical companies such as Merck, Novartis, Exelixis and Pfizer, successfully driving multi-functional teams through early phase to late phase oncology clinical development and timely delivering of multiple global regulatory submissions (3 INDs, 1 NDA, 1 BLA, 2 MAAs). Before joining the industry, Dr. Ru was the principal scientist and sub-investigator of Clinical Breast Care Project sponsored by the United States Department of Defense. Dr. Ru completed her post-doctoral training in Bioscience Division at Los Alamos National Laboratory in 2003 and received her Ph.D. in Chemistry from Tsinghua University in 2001.


Agenda Day 2 @ 3:15

Progress of chimeric antigen receptor (CAR) T-cells as an immuno-oncology treatment

  • Preliminary clinical outcomes of FIM clinical trial of CAR-GPC3 T cells in patients with advanced hepatocellular carcinoma
  • Bottlenecks in tech transfer for CAR-GPC3 T cells cross board manufacturing
  • Regulatory considerations when planning CAR-T clinical trials in China vs in US

back to speakers